METHOD FOR COMBINED TREATMENT OF METASTATIC COLORECTAL CANCER IN PATIENTS WITH RESECTABLE HEPATIC METASTASES AND IN THE ABSENCE OF MUTATIONS IN THE KRAS AND BRAF GENES Russian patent published in 2022 - IPC A61K31/4375 A61K31/282 A61K31/519 A61K31/513 A61K39/395 A61P35/00 A61P35/04 

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, namely to oncology, and can be used for combined treatment of metastatic colorectal cancer in patients with resectable hepatic metastases and in the absence of mutations in the KRAS and BRAF genes. The method includes drop administration of cetuximab 500 mg/m² intravenously on day 1, irinotecan intravenously on day 1, oxaliplatin 85 mg/m² intravenously on day 1, drop infusion of leucovorin 200 mg/m² intravenously on day 1, and drop administration of 5-fluorouracil intravenously. Three courses of preoperative treatment are executed, wherein infusion of leucovorin is executed on days 1 and 2 at 200 mg/m², the dose of irinotecan is 165 mg/m², infusion of 5-fluorouracil at a dose of 3,200 mg/m² is executed for 46 hours, the gap between courses is 12 days. After completing the preoperative treatment, in the presence of an objective tumour response, simultaneous radical surgery is performed on the primary tumour and on the metastatic foci in the liver R0, 3 courses of adjuvant treatment are conducted in the postoperative period according to the previous scheme without administering cetuximab.

EFFECT: use of the invention provides a possibility of improving the results of combined treatment of metastatic colorectal cancer with isolated liver damage by increasing the frequency of objective responses of the tumour and reducing the amount of adverse events during medicinal anti-tumour treatment, increasing the frequency of performing parenchyma-preserving radical liver resections (R0), as well as increasing the overall and relapse-free survival of patients.

1 cl, 2 ex